SCHEMBL19742683

SCHEMBL19742683

CN(CCNC(=O)OC(C)(C)C)c1ccc(N)cc1CS(C)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
CA1 P00915 9/20 0.40
CA2 P00918 9/20 0.40
CA12 O43570 5/20 0.40
CA9 Q16790 5/20 0.40
NQO2 P16083 1/20 0.38
MALT1 Q9UDY8 1/20 0.37
BRD4 O60885 2/20 0.36
IDO1 P14902 2/20 0.36
SUV39H2 Q9H5I1 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
GLA P06280 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
XBP1 P17861 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29352527 1.00 CKS1B (0.41) CKS1BSKP1SKP2CA1CA2
SCHEMBL29357394 0.85 ALOX5 (0.42) CKS1BSKP1SKP2CA1CA2
SCHEMBL19742780 0.85 ALOX5 (0.42) CKS1BSKP1SKP2CA1CA2
SCHEMBL19742636 0.84 CYP19A1 (0.34) CA1CA2CA9ALDH1A1HTT
SCHEMBL19742538 0.83 CKS1B (0.42) CKS1BSKP1SKP2CA1CA2
SCHEMBL29352573 0.83 CYP19A1 (0.33) CA1CA2CA12CA9MAPT
SCHEMBL29352653 0.83 CA1 (0.35) CA1CA2CA12CA9NQO2
SCHEMBL30279944 0.80 L3MBTL1 (0.35) MAPT
SCHEMBL19742673 0.80 PPIA (0.33) CA1CA2CA12CA9MALT1
SCHEMBL29357526 0.80 PPIA (0.33) CA1CA2CA12CA9MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3474855-B1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS INC (US) 2022-01-26 EP disclosed
EP-3474855-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF Polaris Pharmaceuticals, Inc. (US) 2019-05-01 EP disclosed
US-10227344-B2 CK2 inhibitors, compositions and methods thereof POLARIS PHARMACEUTICALS, INC. (US) 2019-03-12 US disclosed
US-10227344-B2 CK2 inhibitors, compositions and methods thereof POLARIS PHARMACEUTICALS, INC. (US) 2019-03-12 US disclosed
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS 2017-12-28 US disclosed
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS 2017-12-28 US disclosed
WO-2017223432-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS (US) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF CSNK1A1, CSNK2A1, CSNK2A3 CKS1B 13/4885SKP1 130/4885SKP2 20/4885
US-10227344-B2 CK2 inhibitors, compositions and methods thereof CSNK1A1, CSNK2A1, CSNK2A3 CKS1B 13/4885SKP1 130/4885SKP2 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.